Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SDF-1 alpha, also known as C-X-C motif chemokine 12 (CXCL12), is a small (8 kDa), 68-89 amino acid peptide belonging to the CXC chemokine family. It is ubiquitously expressed and plays crucial roles in various biological processes including cell growth, migration, proliferation, differentiation, and survival. It primarily signals through the G-protein coupled receptor CXCR4, and also through CXCR7, to mediate cell chemotaxis, tissue repair, angiogenesis, and inflammatory responses. SDF-1 alpha is involved in the homing of hematopoietic stem cells, T cells, monocytes, and endothelial progenitor cells, and is being investigated for therapeutic applications in conditions such as ischemic cardiomyopathy, peripheral artery disease, osteoarthritis, and rheumatoid arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SDF-1 alpha.